Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12524900 | 0.85 | MRGPRX4 (0.62) | MAOBMRGPRX4IDO1AGXTHTR6 | |
| SCHEMBL3321494 | 0.85 | MAOB (0.65) | MAOBMRGPRX4IDO1AGXTHTR6 | |
| SCHEMBL1406548 | 0.84 | MAOB (0.60) | MAOBMRGPRX4IDO1AGXTEGFR | |
| SCHEMBL1407008 | 0.83 | FFAR4 (0.56) | MAOBMRGPRX4MAPTL3MBTL1 | |
| SCHEMBL29514868 | 0.82 | MAOB (0.61) | MAOBMRGPRX4IDO1AGXTEGFR | |
| SCHEMBL143579 | 0.82 | MAOB (0.61) | MAOBIDO1AGXTHTR6CYP1A2 | |
| SCHEMBL156718 | 0.82 | MAOB (0.61) | MAOBMRGPRX4IDO1AGXTEGFR | |
| SCHEMBL29388015 | 0.82 | MAOB (0.61) | MAOBMRGPRX4IDO1AGXTEGFR | |
| SCHEMBL12301124 | 0.81 | MRGPRX4 (0.58) | MAOBMRGPRX4IDO1AGXTHTR6 | |
| SCHEMBL15701532 | 0.81 | MRGPRX4 (0.64) | MAOBMRGPRX4IDO1AGXTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838712-B8 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2011-10-12 | — | — | EP | disclosed |
| US-7947676-B2 | 2-{[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]oxy-}ethanol; erbB2 receptor tyrosine kinase inhibitor; anticarcinogenic, antitumor agnet; solid tumor and nonsolid such as leukaemia, multiple myeloma and lymphoma | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | disclosed |
| EP-1838712-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| EP-1511718-B1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| CN-100482638-C | N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors | HOFFMANN LA ROCHE (CH) | 2009-04-29 | — | — | CN | disclosed |
| US-20080206330-A1 | 4-quinazolinamine active ingredient; inhibitor of EGFR and erbB2 protein tyrosine kinase; cancer; tablets manufactured economically, conveniently shipped, stored, dispensed; accurate dosage, ease of administration, portability | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| US-20080108613-A1 | Pyrazolopyrimidine Compounds as Antitumor Agents | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| EP-1838712-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006064196-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-7053245-B2 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050283019-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2005-12-22 | — | — | US | disclosed |
| CN-1656057-A | N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors | HOFFMANN LA ROCHE (CH) | 2005-08-17 | — | — | CN | disclosed |
| EP-1511718-A1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2004-10-21 | — | — | US | disclosed |
| US-6762320-B2 | MONOAMINE OXIDASE B INHIBITORS; ALZHEIMER'S DISEASE, SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-07-13 | — | — | US | disclosed |
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003099763-A1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | MAOB 1/4885MRGPRX4 1690/4885IDO1 557/4885 |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, CBR1 | MAOB 1/4885MRGPRX4 1719/4885IDO1 515/4885 |
| US-20050283019-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | MAOB 1/4885MRGPRX4 1058/4885IDO1 654/4885 |
| US-20080108613-A1 | Pyrazolopyrimidine Compounds as Antitumor Agents | ERBB2, ERBB3, ERBB4 | MAOB 2132/4885MRGPRX4 1967/4885IDO1 1272/4885 |
| US-20080206330-A1 | 4-quinazolinamine active ingredient; inhibitor of EGFR and erbB2 protein tyrosine kinase; cancer; tablets manufactured economically, conveniently shipped, stored, dispensed; accurate dosage, ease of administration, portability | ERBB2, ERBB4, PTK2B | MAOB 3145/4885MRGPRX4 3946/4885IDO1 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.